Previous 10 | Next 10 |
2023-03-07 11:35:38 ET Jerome Powell takes center stage today and tomorrow with his semiannual testimony. While it has brought plenty of volatility to the stock market, some asset classes are generally experiencing a bit more as a result. I’m talking about penny stocks and there ...
2023-03-07 08:38:30 ET ThredUp ( TDUP ) +17% on Q4 earnings . Protagonist Therapeutics ( NASDAQ: PTGX ) +20% on positive topline results for Phase 2b FRONTIER 1 clinical trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis. BYND Cannas...
2023-03-06 17:00:36 ET Precigen press release ( NASDAQ: PGEN ): FY GAAP EPS of -$0.40 misses by $0.41 . Revenue of $26.91M (+88.6% Y/Y) misses by $27.46M . Shares +1.74% AH. For further details see: Precigen GAAP EPS of -$0.40 misses by $0.41, rev...
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates PR Newswire – Achieved significant clinical progress for UltraCAR-T ® and AdenoVerse ™ investigational therapeutics in 2022 – –...
After a promising start to 2023, clinical-stage biotech stocks reversed course this week. For example, shares of the developmental-stage biotechs Altimmune (NASDAQ: ALT) , Foghorn Therapeutics (NASDAQ: FHTX) , and Precigen (NASDAQ: PGEN) all dropped by double digits du...
(NewsDirect) New hope may be on the horizon for sufferers of Recurrent Respiratory Papillomatosis, or RRP, a rare and debilitating disease that typically requires patients to undergo multiple surgeries each year to remove benign tumors called papillomas, that grow in the respiratory tract...
Are You Watching Penny Stocks? These Insiders Are Are you trying to find penny stocks to buy? What about seeing what insiders are doing? When the people who work inside a company, like the CEO or other executives, buy shares, it can be a bullish sign. Some traders presume these insiders t...
Summary Last week's PRGN-2012 results were impressive and perhaps the first genuine validation of the AdenoVerse therapeutic platform. Though it did retire $157 million in convertible notes in late 2022, Precigen has a mediocre balance sheet and the ticker moves with jerk-neck volatilit...
Precigen Announces Closing of Public Offering of Common Stock PR Newswire GERMANTOWN, Md. , Jan. 27, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Prec...
Stocks with share prices under $5 (aka " penny stocks ") are typically too risky to consider. The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Which beaten-down innovation stocks are worth checking out righ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...